Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib with R-CHOP in DLBCL
NCT03571308Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by University Hospital Southampton NHS Foundation Trust. Started Jun 2017; status: completed.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03571308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571308.